Merus und myTomorrows kündigen Ausbau ihrer Zusammenarbeit an, um Aufmerksamkeit für Screening und klinische eNRGy-Studie zur Behandlung von Krebspatienten mit Tumoren mit Neuregulin-1-Fusionen zu erhöhen
October 13, 2020 14:35 ET
|
Merus N.V.
UTRECHT, Niederlande, und CAMBRIDGE, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- myTomorrows, ein globales Unternehmen im Bereich Gesundheitstechnologien, und Merus N.V. (Nasdaq: MRUS), ein Unternehmen...
Merus et myTomorrows annoncent l'extension de leur collaboration pour le dépistage et la sensibilisation à l'essai clinique eNRGy pour les patients atteints d'un cancer avec des tumeurs à fusion du gène neuréguline 1
October 13, 2020 14:35 ET
|
Merus N.V.
UTRECHT, Pays-Bas, et CAMBRIDGE, Massachusetts, 13 oct. 2020 (GLOBE NEWSWIRE) -- myTomorrows, entreprise mondiale spécialisée dans les technologies de la santé, et Merus N.V. (Nasdaq : MRUS),...
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors
October 12, 2020 17:00 ET
|
Merus N.V.
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- myTomorrows, a global health technology company, and Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company...
Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer
July 10, 2017 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 10, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that 12 pancreatic patients are currently undergoing treatment with single-agent Ampligen...
Hemispherx Announces First Shipment of Newly Manufactured Rintatolimod (Ampligen®) for Sale to Early Access Program in Europe
January 26, 2017 10:51 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that an order of newly manufactured rintatolimod (Ampligen®) for sale utilizing the Early Access...
Hemispherx Biopharma Announces Extension of Rintatolimod European Early Access Program (EAP) to Pancreatic Cancer Patients
January 11, 2017 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the "Company") announced today that the rintatolimod European early access program (EAP) designed...
Hemispherx Enters Into an Agreement With myTomorrows for an Early Access Program for Rintatolimod in Europe
August 10, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has executed an agreement with Impatients, N.V., a...